Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas [5]

B. Falini; D. Lenze; R. Hasserjian; S. Coupland; D. Jaehne; C. Soupir; A. Liso; M. P. Martelli; N. Bolli; F. Bacci; V. Pettirossi; A. Santucci; M. F. Martelli; S. Pileri; H. Stein

doi:10.1038/sj.leu.2404699

Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas [5]

B. Falini, D. Lenze, R. Hasserjian, S. Coupland, D. Jaehne, C. Soupir, A. Liso, M. P. Martelli, N. Bolli, F. Bacci, V. Pettirossi, A. Santucci, M. F. Martelli, S. Pileri, H. Stein

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1566-1570
Number of pages	5
Journal	Leukemia
Volume	21
Issue number	7
DOIs	https://doi.org/10.1038/sj.leu.2404699
Publication status	Published - Jul 2007

ASJC Scopus subject areas

Hematology
Cancer Research

Access to Document

10.1038/sj.leu.2404699

Cite this

Falini, B., Lenze, D., Hasserjian, R., Coupland, S., Jaehne, D., Soupir, C., Liso, A., Martelli, M. P., Bolli, N., Bacci, F., Pettirossi, V., Santucci, A., Martelli, M. F., Pileri, S., & Stein, H. (2007). Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas [5]. Leukemia, 21(7), 1566-1570. https://doi.org/10.1038/sj.leu.2404699

Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas [5]. / Falini, B.; Lenze, D.; Hasserjian, R.; Coupland, S.; Jaehne, D.; Soupir, C.; Liso, A.; Martelli, M. P.; Bolli, N.; Bacci, F.; Pettirossi, V.; Santucci, A.; Martelli, M. F.; Pileri, S.; Stein, H.

In: Leukemia, Vol. 21, No. 7, 07.2007, p. 1566-1570.

Research output: Contribution to journal › Article › peer-review

Falini, B, Lenze, D, Hasserjian, R, Coupland, S, Jaehne, D, Soupir, C, Liso, A, Martelli, MP, Bolli, N, Bacci, F, Pettirossi, V, Santucci, A, Martelli, MF, Pileri, S & Stein, H 2007, 'Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas [5]', Leukemia, vol. 21, no. 7, pp. 1566-1570. https://doi.org/10.1038/sj.leu.2404699

Falini, B. ; Lenze, D. ; Hasserjian, R. ; Coupland, S. ; Jaehne, D. ; Soupir, C. ; Liso, A. ; Martelli, M. P. ; Bolli, N. ; Bacci, F. ; Pettirossi, V. ; Santucci, A. ; Martelli, M. F. ; Pileri, S. ; Stein, H. / Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas [5]. In: Leukemia. 2007 ; Vol. 21, No. 7. pp. 1566-1570.

@article{83cc5044800b423f8dd9b382ea35e393,

title = "Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas [5]",

author = "B. Falini and D. Lenze and R. Hasserjian and S. Coupland and D. Jaehne and C. Soupir and A. Liso and Martelli, {M. P.} and N. Bolli and F. Bacci and V. Pettirossi and A. Santucci and Martelli, {M. F.} and S. Pileri and H. Stein",

year = "2007",

month = jul,

doi = "10.1038/sj.leu.2404699",

language = "English",

volume = "21",

pages = "1566--1570",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas [5]

AU - Falini, B.

AU - Lenze, D.

AU - Hasserjian, R.

AU - Coupland, S.

AU - Jaehne, D.

AU - Soupir, C.

AU - Liso, A.

AU - Martelli, M. P.

AU - Bolli, N.

AU - Bacci, F.

AU - Pettirossi, V.

AU - Santucci, A.

AU - Martelli, M. F.

AU - Pileri, S.

AU - Stein, H.

PY - 2007/7

Y1 - 2007/7

UR - http://www.scopus.com/inward/record.url?scp=34250721029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250721029&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2404699

DO - 10.1038/sj.leu.2404699

M3 - Article

C2 - 17443224

AN - SCOPUS:34250721029

VL - 21

SP - 1566

EP - 1570

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 7

ER -